Iridex Corp
Como a empresa evoluiu, ano a ano. Receita e dívida vêm dos relatórios anuais — na maioria das empresas, os 10-K entregues à SEC desde 2009; os dividendos, dos próprios pagamentos.
As barras são um saldo na data de fechamento; as linhas são o que aconteceu ao longo do ano. Receita acima do patrimônio é o normal, não anomalia — significa que a empresa gira o capital mais de uma vez por ano.
Grandes gestores que reportaram esta ação no 13F mais recente.
▼ -91.9% em 5A.
hoje você teria $81.59▼ -91.8%
Com dividendos reinvestidos e desdobramentos considerados. Preço passado diz o que aconteceu, não o que vai acontecer.
Os últimos 17 anos fechados. Cada múltiplo usa o preço de fechamento daquele ano e os números reportados naquele ano — não os de hoje. O alcance é o dos relatórios anuais que temos.
| Indicador | Mediana | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Preço no fim do ano | $1.14 | $1.68 | $2.81 | $2.01 | $6.11 | $2.51 | $2.23 | $4.70 | $7.62 | $14.06 | $9.29 | $8.60 | $10.17 | $3.90 | $3.74 | $3.92 | $3.07 | |
Empresas de tamanho parecido em Healthcare, para comparar. As colunas são as mesmas de cima, na mesma ordem.
| Ação | Preço | P/L | P/VP | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| QNRXQuoin Pharmaceuticals Ltd. | $6.12 | — | 0.7x | — | -575.73% | $12.29M |
| HCTIHealthcare Triangle, Inc. | $0.84 | — | 0.1x | — | -57.41% | $12.36M |
| MBRXMoleculin Biotech, Inc. | $0.65 | 0.0x | 0.4x | — | -1371.64% | $12.66M |
| ASBPAspire Biopharma Holdings, Inc. |
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat uncontrolled and refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Descrição da empresa fornecida pelo Yahoo Finance. A descrição é publicada pela fonte apenas em inglês.
| P/L |
| 14.4x |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| 185.8x |
| 8.9x |
| 46.2x |
| 24.4x |
| 14.4x |
| 13.1x |
| 11.8x |
| P/Receita | 1.1x | 0.4x | 0.6x | 0.9x | 0.6x | 1.8x | 1.1x | 0.7x | 1.5x | 2.1x | 3.5x | 2.2x | 2.0x | 2.7x | 1.0x | 1.0x | 1.1x | 1.0x |
| P/VP | 2.5x | 4.0x | 13.5x | 4.8x | 1.9x | 4.2x | 2.2x | 1.4x | 2.1x | 2.9x | 4.1x | 2.8x | 2.5x | 3.9x | 1.5x | 1.5x | 1.8x | 2.0x |
| EPS | -$0.26 | -$0.54 | -$0.59 | -$0.47 | -$0.34 | -$0.46 | -$0.64 | -$1.05 | -$1.11 | -$1.15 | $0.05 | $0.97 | $0.22 | $0.16 | $0.26 | $0.30 | $0.26 |
| Margem líquida | -9.69% | -8.42% | -18.31% | -18.45% | -13.25% | -9.69% | -17.41% | -20.28% | -30.08% | -30.94% | -25.38% | 1.14% | 23.45% | 5.83% | 4.25% | 7.87% | 9.43% | 8.33% |
| ROE | -29.91% | -90.15% | -424.89% | -100.50% | -43.80% | -22.43% | -36.44% | -38.82% | -42.77% | -42.16% | -29.91% | 1.41% | 29.75% | 8.63% | 6.56% | 11.64% | 15.68% | 17.20% |
Mediana, e não média: um único ano de lucro quase zero dá P/L de 400 e arrastaria a média sozinho. Anos com P/L acima de 200x ficam de fora, o mesmo corte do preço justo — por isso esta mediana bate com o método “histórico da própria empresa” abaixo. Preço e LPA não têm mediana: são séries que crescem.
| $8.51 |
| — |
| 0.9x |
| — |
| -1032.14% |
| $11.94M |
| PDSBPDS Biotechnology Corp | $0.21 | — | — | — | -543.97% | $11.8M |
| SNTISenti Biosciences Holdings, Inc. | $0.38 | — | 4.6x | — | -466.46% | $11.74M |